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THE ROLE OF RETINOIC ACID RELATED ORPHAN RECEPTOR ALPHA 
IN AGE-RELATED MACULAR DEGENERATION 
HAI HOANG 
ABSTRACT 
 Age-related macular degeneration (AMD) is a prevalent cause of vision loss and 
irreversible blindness that affects more than 11 million Americans. AMD is a 
multifactorial disease with a number of genetic, demographic, and environmental risk 
factors. Currently the etiology of AMD is still unclear and there are no effective cure for 
this devastating disease, but recent studies have demonstrated that RORA is a candidate 
gene involved in AMD pathophysiology. RORA is a critical regulator of multiple 
biological processes and has been implicated in various physiological processes including 
circadian rhythm, lipid metabolism, photoreceptor development, autism, and 
inflammation. Our current study will explore in depth the role of RORA in AMD. We 
will look at the effects of RORA in the retina of mice. Localization studies of retinal 
tissues obtained from mice with a conditional knockout of RORA in epithelial cells 
showed little effect of RORA on structural cells of the retina. However, there was a 
decrease in VEGF and TGF-B proteins in RORA knockout. This is an interesting finding 
because VEGF and TGF-B has an important function in angiogenesis and 
neovascularization which are pathophysiological effects of AMD. In addition, we will try 
to identify gene targets of RORA that have also been linked with AMD. By identifying 
the targets of RORA and discovering how RORA regulates these targets, we hope to 
better understand the role of RORA in AMD pathophysiology. ChIP-seq and software 
  vi 
analysis of the data was performed to identify all genomic targets of RORA linked with 
AMD. A number of promising genes were found in both RORA and AMD networks. The 
next step of this study is to perform quantitative analysis of these genes and how their 
expression is affected by RORA. Also, we will perform additional conditional RORA 
knockout models in cone cells and developing retinal cells to further understand the role 
of RORA in the retina and AMD pathogenesis.  
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INTRODUCTION 
 
Age-Related Macular Degeneration (AMD) 
 Age-related macular degeneration (AMD) is a prevalent cause of vision loss and 
irreversible blindness that affects more than 11 million Americans according to the 
BrightFocus Foundation (2013). AMD is a multifactorial disease with a number of 
genetic, demographic, and environmental risk factors. The strongest risk factors include 
age, cigarette smoking, diet, and race (Coleman et al., 2008). 
Risk factors  
beyond your 
control 
Facts 
Age Adults over age 50 
Family History AMD runs in families (up to three times the risk) 
Gender Women are more vulnerable (up to two times the risk) 
Coloring Those with light colored irises and skin may be more susceptible 
Risk factors  
within your 
control 
Facts 
Diet Low intake of antioxidant vitamins and minerals puts you at higher risk. 
Canadians 50+ often do not consume Canada Food Guide’s recommendations 
of 5 to 10 servings of fruits and vegetables daily 
Smoking Smokers are more susceptible (up to six times the risk) 
Excessive 
exposure  
to sunlight 
Extended sunlight exposure associated with 10 year incidence of early AMD 
Excessive 
weight /obesity 
Excessive weight increases risk, and a high body mass index increases risk of 
progression 
 
Table 1: Risks of AMD include age, smoking, family history, demographics, and 
diet:  AMD is a multifactorial disease with a number of risk factors. This chart discusses 
the most common risks of AMD. Obtained from Family Health Magazine, 2012 
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AMD causes vision impairment through deterioration of the macula, the center of 
the retina responsible for central vision. This is a slow progressing disease that develops 
over a number of years, often asymptomatically in the early stages. (Coleman HR et al., 
2008). Early and intermediate stages of AMD are characterized by drusen formation and 
pigmentary abnormalities, and have a high chance of progression to advanced AMD 
(Age-Related Eye Disease Study Research Group (AREDSRG), 2005). Drusens are 
extracellular debris and lipid deposits that localize in between the retinal pigment 
epithelium (RPE) and Bruch’s membrane. They range in size, color, distribution, and 
shape. They also, tend to increase with age, and are linked to RPE atrophy and 
dysfunction (Abdelsalam et al., 1999; Bhutto and Lutty, 2012). RPE cells are essential for 
vision by being responsible for many complex functions that involve supporting retinal 
cells (Strauss, 2005).  They provide support to retinal cells by providing nutrients, 
removing waste products, healing wounds, secreting growth factors, and sustaining the 
choroid and photoreceptors cells (Marshall, 1987; Streilein et al., 2002; Nita et al., 2014). 
There are two forms of advanced AMD: dry and wet AMD. Dry AMD is the more 
common form of AMD, consisting of around 85-90% of total cases. Dry AMD, also 
known as non-exudative or geographic atrophy, is characterized by atrophy of the cells in 
the macula responsible for central vision.  In dry AMD, drusen accumulates between the 
retina and choroid which leads to breakdown of retinal pigment epithelial (RPE) cells. 
RPE atrophy (Geographic atrophy) results in degradation of the photoreceptors leading to 
decrease in central visual function. Dry AMD progresses slowly, but can manifest into 
wet AMD in 10% of patients (Sunness et al., 1999). 
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Wet AMD, also known as exudative or neovascular AMD, occurs in 10% of all 
AMD cases. Choroidal neovascularization (CNV) is a signature clinical hallmark of wet 
AMD. CNV is caused by decrease in oxygen and growth factors due to atrophy and 
dysfunction of the RPE (Bird, 2003). Formation of new blood vessels in the choroid can 
invade into the retina through Bruch’s membrane and the RPE (Bhutto and Lutty, 2012; 
Das and McGuire 2003). These vessels are more susceptible to leaking blood and fluids, 
causing damage and scars, and leading to acute, severe central vision loss (Ding et al., 
2008). 
Currently there are treatments for some cases of wet AMD, which includes laser 
treatments and intravitreal injections of vascular epithelial growth factor inhibitors to 
combat progression of the disease (Keane et al., 2015). In addition, studies have shown 
taking antioxidant multivitamins and zinc have helped to slow the progress of dry AMD 
(AREDSRG, 2001). Even with the recent advancement in treating patients with AMD, 
the etiology and pathogenesis of AMD is poorly understood. Currently, there is no known 
cure of AMD or effective prevention of the disease. Therefore it is important to discover 
new methods that can help detect early manifestation of AMD. Due to the progressive 
nature of the disease, it is beneficial to understand the development and progression of 
the disease to provide better treatments. 
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Figure 1: Dry AMD contains the presence of drusen while wet AMD contains the 
presence of neovascularization in the retina: This figure illustrates the 
pathophysiological findings of advanced AMD. Dry AMD is characterized by drusen 
formation causing RPE dysfunction which leads to retinal cells degeneration. Wet AMD 
is characterized by choroidal neovascularization, which can cause leaking blood and fluid 
into the retina. Figure obtained from BrightFocus foundation, 2013. 
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Retinoic-Acid-Related Orphan Receptor Alpha(RORA) 
Recent studies on the interaction between genetic and environmental factors in the 
disease have implicated a number of genes in the pathogenesis of AMD (Scholl et al., 
2007). A promising study, performed previously in this research lab, have linked retinoic-
acid-related orphan receptor alpha (RORA or NR1F1) to the pathogenesis of AMD 
(Silveira et al., 2009). RORA is a member of the nuclear receptor superfamily. Nuclear 
receptors are a type of transcription factor because they can directly bind to DNA to 
regulate gene expression. Many nuclear receptors have ligands that cause conformational 
change once bound. This conformational change activates the nuclear receptor enabling 
to interact with specific response elements, and subsequently alter gene expression 
(Olefsky, 2001). Nuclear receptors are a diverse family, with a total of 48 known human 
nuclear receptors (Zhang et al., 2004). They are involved in the etiology of many diseases 
and functions in almost all physiological processes including development and 
homeostasis. Currently, it is a promising area of research, which has major implications 
in physiology, therapeutic treatments, and drug development. 
Orphan receptors are a group of nuclear receptors that currently do not have any 
known ligands. RORA is an orphan receptor since its endogenous ligand is not fully 
agreed upon. Many recent studies have identified potential ligands that can modulate this 
NR to identify/understand its physiological role, but none has been fully agreed upon 
(Solt et al., 2012). RORA is a critical regulator of multiple biological processes and has 
been implicated in various physiological processes including circadian rhythm, lipid 
metabolism, photoreceptor development, autism, bone morphogenesis, and inflammation 
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(Jetten et al., 2009). Its expression is distributed widely thorough several organs and 
tissues including brain, liver, testis, skin, and bone (Giguere et al., 1994). 
 
Figure 1: RORA is a transcriptional factor that has many physiological functions. 
This diagram illustrates how RORA binds to its response element (AGGTCA preceded 
by 6 A/T) to affect the transcription of many target genes. RORA has a wide variety of 
gene targets in almost all physiological functions. It is also been implicated in a number 
of diseases, which makes it an ideal target for novel therapeutic treatments. Obtained 
from National Institute of Environmental Health Sciences, 2011 
 
RORA has a direct role in the retina, specifically in photoreceptor development. 
RORA expression is found in GCL, INL, and cone photoreceptors in mouse adult retinas. 
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It is also highly expressed throughout the retina during embryonic development where it 
is involved in retinal cone photoreceptor cells development (Fujieda et al., 2009).  
RORA has been found to have a role in circadian rhythms. Circadian rhythms 
have an essential role in regulation of almost all normal physiology processes and 
behavior. Many cells contain its own circadian oscillator that operates in an independent 
manner. However, all of the cells are coordinated by the master circadian clock located in 
the brain (Ko and Takahashi, 2006). The master clock is in turn regulated in part by the 
light-dark input by the visual photoreceptor systems in the retina. A number of genes 
(BMAL1, CLOCK, PER, CRY) that are essential in the molecular circuitry of circadian 
clock are regulated by RORA through positive and negative feedback loop pathways 
(Isojima 2003). Circadian rhythms have a role in metabolism thus implicating RORA to 
have an intermediate role to couple circadian clock with metabolism. Fluctuations in 
daily levels of glucose, lipids, insulin, and other important molecules in metabolism 
suggest that the circadian cycle plays an important role in regulation of metabolic 
pathways. Disruption of this cycle can result in manifestation of metabolic disease such 
as obesity, diabetes, and cardiovascular defects which all have AMD risk associations 
(Duez and Staels 2008).  
In addition, RORA has been directly implicated in cellular metabolism especially 
lipid and cholesterol metabolism. Reduced expression of cholesterol transporters 
(ABCA1, ABCA8, APOA1) is a proposed mechanism in which RORA affects 
cholesterol and lipoproteins levels (Lau et al., 2008). Also, cholesterol has been reported 
to be a potential natural endogenous ligand of RORA (Kallen el al., 2002). This is a 
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possible pathway in which RORA can affect AMD, since lipid metabolism plays a role in 
formation of drusen and angiogenesis.  
 Angiogenesis is one of the clinical manifestations of advanced neovascular AMD. 
Low oxygen levels play an important role in inducing angiogenesis, vasculogenesis, and 
tumorigenesis (Besnard et al., 2001). Studies have shown that RORA is upregulated in 
not only hypoxic conditions, but also under oxidative stress. Oxidative stress has also 
been implicated in AMD due to its pro-inflammatory responses that leads to retinal 
damage (Beatty et al., 2000). AMD development has been strongly linked to the immune 
system and inflammatory pathway (Klein et al., 2005). This is another pathway where 
RORA and AMD are linked.    
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SPECIFIC AIMS AND OBJECTIVE 
 
Age-related macular degeneration is a devastating disease that affects millions of 
people worldwide, yet the etiology and pathogenesis of AMD is not fully understood. A 
recent study by Jun et al. (2011) has demonstrated RORA as a candidate gene involved in 
AMD pathophysiology. RORA has numerous physiological functions which are common 
in AMD pathology. Our current study will further explore the role of RORA in AMD. 
We will look at the effects of RORA in the retina of mice by immunohistochemistry. 
Antibodies against retinal cell-specific markers and proteins of interest will be used to 
detect their expression in the retina. In addition, we will try to identify gene targets of 
RORA that have also been linked with AMD. By identifying the targets of RORA and 
discovering how RORA regulates these targets, we hope to better understand the role of 
RORA in AMD pathophysiology. This study is an important step to understanding this 
complex disease and is necessary to form novel therapeutic treatments in the future. 
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METHODS 
 
MICE 
All mice were bred and maintained under standard conditions at Schepens Eye 
Research Institute. Rora(flox/flox) were crossed with Cdh5-Cre to produce offsprings 
with both mutations (Rora(flox/flox) x Cdh5-Cre). Tissues were harvested from control, 
wild type C57BL6/J (WT) mice, Rora(flox/flox) mice, and Cdh5-cre.  
 
GENOTYPING 
Mice were genotyped by PCR to ensure each mutation were present.  Tail samples 
were collected and DNA was extracted for genotyping using the isopropanol method. 
Tail samples were submerged in a solution of 250µl tail buffer and 7µl proteinase K, and 
incubated for 2 hours at 65℃, vortexing every 10 minutes. 200µl of 5M ammonium 
acetate was added to the solution, and then incubated on ice for 15 minutes. Solution was 
centrifuged for 20 minutes at 13,000 RPM. Afterwards, the supernatant was transferred to 
a new tube containing 750µl isopropanol, and then centrifuged for 10 minutes at 16,000 
RPM. The supernatant was removed, and 1 ml of 70% ethanol was added.  Solution was 
centrifuged for 5 minutes at 16,000 rpm. Supernatant was discarded, and pellet was dried 
for 5 minutes on heat block at 55 ℃. 30µl of DEPC treated water was added, and tube 
was incubated for 10 min at 55℃. The concentration of DNA extracted was measured 
using Thermo Scientific NanoDrop 2000 Spectrophotometer. 
PCR master mix component (per sample): 10x PCR buffer (1µl) (Roche Life 
Sciences), 40mM dNTP (0.20 µl) (Roche Life Sciences), 10µM forward primer (0.25 µl), 
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10µM reverse primer (0.25µl), Taq Polymerase 5U/µl (0.1 µl) (Roche Life Sciences), 
DNA sample 50 ng/µl (0.7µl). Final reaction = 10 µl. The following primers were used: 
RORA-flox (Forward, 5’- TCT GAA TCC ACC ATA CTT CC -3’, Reverse, 5’- AGG 
TCT GCC ACG TTA TCT G -3’) (Eurofins MWG Operon), Cdh-Cre (Forward, 5’- GTG 
AAA CAG CAT TGC TGT CAC TT -3’, Reverse, 5’- GCG GTC TGG CAG TAA AAA 
CTA TC -3’) (Eurofins MWG Operon).  
All reactions were performed in 200µl PCR tubes, and were run in a Bio-Rad 
C1000 Touch Thermal Cycler. Cycle parameters for Rora-floxed: 1) 95℃ for 3 minutes, 
2) 95℃ for 15 sec, 3) 65℃ for 30 seconds, decrease 1℃/cycle, 4) 72℃ for 40 seconds, 5) 
Go to step 2 for 10 cycles, 6) 95℃ for 15 seconds, 7) 55℃ for 30 seconds, 8) 72℃ for 40 
seconds, 9) Go to step 6 for 30 cycles, 10) 4℃ hold until refrigerate product. Cycle 
parameters for Cdh-cre: 1) 95℃ for 3 minutes, 2) 95℃ for 30 seconds, 3) 51.7℃ for 1 
minute, 4) 72℃ for 1 minute, 5) Repeat steps 2-4 for 34 cycles, 6) 72℃ for 2 minutes, 8) 
12℃ hold. Products were analyzed on 2% agarose gel with ethidium bromide staining. 
Product size: 323 bp WT RORA, 394 bp mutant RORA-flox, 100 bp Cre product. 
 
IMMUNOHISTOCHEMISTRY 
Eyes from wild type B6 mice, Rora-floxed, Cdh-Cre, and Rora/Cdh mice were 
collected for paraffin embedding. Eyes were stored in Methanol: Acetic Acid (3:1) 
fixative or 4% Paraformaldehyde (PFA) fixative overnight at 4℃. Eyes were then placed 
in embedding cartridges with the following solution: 70% ethanol for 2 hours, 95% 
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ethanol for 2 hours, 100% ethanol for 2 hours, xylene for 1 hour, paraffin overnight. 
Tissue blocks were sectioned at 5µm and collected on coated slides.   
Deparaffinization of tissue sections were performed using xylene twice for 5 
minutes each. Afterwards, tissues were dehydrated in decreasing ethanol concentration 
(100%, 95%, 70%: twice for 5 minutes each). PFA sections were heat treated with citric 
acid before incubating with primary antibodies. Citric acid treatment of slides involved 
microwaving slides for 60 seconds submerged in 10mM sodium citrate buffer (pH 6.0). 
Sections were then blocked with 2% horse serum diluted in PBS for 45 minutes at room 
temperature to prevent non-specific binding of primary antibodies. Tissue sections were 
incubated with primary antibodies at 4℃ overnight. Secondary antibodies were incubated 
for 45 minutes at room temperature. Cell nuclei were counter stained with 4',6-
diamidino-2-phenylindole (DAPI, diluted 1:200). Finally, sections were mounted with 
glass cover slips using Vectashield (Vector Lab, H-1200). Fluorescence images were 
examined by confocal laser scanning microscope (Leica TCS SP8).  
The following primary antibodies were used: mouse polyclonal antibodies to 
Vascular Epithelial Growth Factor (VEGF, Abcam, Ab1316), rabbit polyclonal 
antibodies to Transforming Growth Factor Beta (TGF-β, Abcam Ab66043), rabbit 
polyclonal antibodies to Glial Fibrillary Acidic Protein (GFAP, EMD  Millipore, 
Ab5804), sheep polyclonal antibodies to Chx10 (CHEMICO International, Ab9014), 
mouse polyclonal antibodies to Calbindin D-28K (Swant, Cb300), rabbit polyclonal 
antibodies to Parvalbumin (Abcam, Ab11427), rabbit polyclonal antibodies to Collagen 
IV (Abcam, ab6586), rabbit polyclonal antibodies to Beta-Tubulin III (Sigma-Aldrich, 
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T2200), rabbit polyclonal antibodies to Neurofilament Light (NFL, EMD Millipore, 
Ab9568), rabbit polyclonal antibodies to Synaptophysin (Abcam, ab52636), rabbit 
polyclonal antibodies to Protein Kinase C alpha (PKC-α, Abcam, Ab31), goat polyclonal 
antibodies to OPN1SW (Santa Cruz Biotechnology, SC-14363), mouse polyclonal 
antibodies to Rhodopsin (EMD Millipore, MAB5316), and rabbit polyclonal antibodies 
to Red/Green Opsin (EMD Millipore, ab5405).  Dilutions of primary antibodies were as 
followed: VEGF 1:100, TGF-β 1:100, GFAP 1:200, Chx10 1:200, Calbindin 1:200, 
Parvalbumin 1:200, Collagen IV 1:400, β-Tubulin III 1:400, NFL 1:200, Synaptophysin 
1:200, PKC-α 1:200, OPN1SW 1:200, Rhodopsin 1:200, Red/Green Opsin 1:200. The 
following secondary antibodies were used: Alexa Fleur 488 goat anti-rabbit IgG (Life 
Technologies, A11008), Alexa Fleur 488 goat anti-mouse IgG (Life Technologies, 
A11001), Alexa Fleur 555 donkey anti-sheep IgG (Life Technologies, A21436). All 
secondary antibodies were diluted 1:400. Both primary and secondary antibodies were 
diluted using 2% horse serum. 
 
CHROMOTIN IMMUNOPRECIPITATION 
Chromatic immunoprecipitation (ChiP) was perfomed as previously described 
(Haider et al., 2009). 8 retinas from B6 mice were obtained. The retina was disrupted 
using a pestle and mortar. 37% formaldehyde was added to the tissue for 60 minutes at 
room temperature in order to crosslink proteins with DNA. The samples were then 
sonicated to shear the DNA. Samples were sonicated with 10 pulses for 1 second. This 
was done 20 times with 10-second pause between pulses. RORA antibody (1μg) was 
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added to bind to cross-linked protein/DNA. Samples were incubated overnight at 4°C on 
a rotating platform. Solution went through a number of washes in order to obtain 
fragments of interest. The remaining fragments were reverse cross-linked by incubating 
with 200mM NaCl and 10mg of Protinase K (to remove proteins) for 5 hours at 65°C. 
Qiagen purification kit was used to purify the DNA samples and concentrations were 
measured Thermo Scientific NanoDrop 2000 Spectrophotometer. Samples were sent to 
for sequencing.  
 
PATHWAY ANALYSIS 
Data from the ChIP assay was used to find statistically significant genes of interest 
regulated or interacted with RORA. Data were analyzed using Ingenuity Pathway 
Analysis (IPA, Ingenuity Systems, www.ingenuity.com) as described in a previous study 
(Jelcick el al., 2011). Networks were generated based on their connectivity. Gene 
identifiers and statistically significant expression values were uploaded into Ingenuity. 
Default cutoffs were set to identify genes whose expression was significantly 
differentially regulated and overlaid onto a global molecular network developed from 
information contained in the Ingenuity Pathways Knowledge Base. Networks were 
algorithmically generated based on their connectivity. Genes or gene products in the 
networks are represented as nodes, and the biological relationship between two nodes is 
represented as an edge (line). Dashed edges represent a weaker relationship than solid 
edges. All edges are supported by at least 1 reference from the literature, from a textbook, 
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or from canonical information stored in the Ingenuity Pathways Knowledge Base. Nodes 
are displayed using various shapes that represent the functional class of the gene product.   
 16 
RESULTS 
 
 
MICE GENOTYPING 
A mouse model was produced with a conditional knockout of RORA in 
endothelial cells by using Cre-lox recombination technology. Rora (Floxed/floxed) was 
crossed with Cdh5-cre to create a new mouse strain with both mutation: RORA 
(floxed/floxed) x Cdh5-cre. This strain is a conditional knockout of RORA in only cells 
that expresses VE-Cadherein which are endothelial cells.  
 Genotyping was performed to ensure that the mice have both mutations (Figure 
3).  Positive control, negative control, and B6 control samples were used to ensure the 
correct mutations were analyzed. RORA-floxed product size was 394bp and RORA WT 
product size was 323bp.  Cdh5-Cre product size was 100bp. The following offspring of 
crossed RORA-floxed and Cdh-cre were shown to have both mutations: 79, 80, 81, 82, 
83, 84, 85, 103, 104, 105 112, 113, 114, 115. The following did not have Rora-flox 
mutations but contained only Cdh-cre: 100, 101, 102, 106, 107, 116.  
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Figure 2: Genotype analysis shows that all mice used contained mutations of both 
RORA- floxed and Cdh5-cre:  Mice were genotyped to determine if mutations were 
present in genome. RORA mutant band is 394 bp and WT RORA is 323 bp. Cdh5-cre 
product is 100bp. The following animals are homozygous for RORA mutant as well as 
Cdh5-cre: 79-85, 103-107, 112-115.  
 
IMMUNOHISTOCHEMISTRY 
Structural proteins (GFAP, NFL, Collagen IV, β-tubulin III): 
Glial fibrillary acidic protein is a type III intermediate filament and functions to 
maintain cell shape and structure. It is a major constituent in astrocytes. It serves as a cell 
specific marker to distinguish between astrocytes from other glial cells. Astrocytes are 
found in the nerve fiber layer (NFL) and ganglion cell layer (GCL) where they provide 
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support for the ganglion cells. GFAP immunoreactivity was confined to the GCL in 
normal B6 mice as well as in the RORA KO (Figure 4). 
Neurofilament light (NFL) are intermediate filament that are major components of 
the neuronal cytoskeleton. It is found primarily in the axons of neurons where its function 
is to provide structural support for axon and regulate axon diameter and shape. 
Immunoreactivity of NFL is found mainly in ganglion cells and horizontal cells in the 
GCL and OPL (Figure 4). 
Collagen IV is a type of collagen that is a major constituent in the basement 
membrane of tissues. Immunoreactivity of collagen IV is seen in the GCL, IPL, OPL, and 
RPE (Figure 4). 
Beta Tubulin III (β-tubulin III) is a major component of microtubules that is 
found only in neurons. It is a marker to distinguish between neurons and glial cells in 
samples of neural tissues. The functions of β-tubulin III include axon guidance and 
maintenance. Immunoreactivity of β-tubulin III is seen in the IPL and OPL (Figure 4). 
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Figure 4: IHC of structural proteins in retina shows no change between RORA 
knockout and WT: GFAP, Collagen IV, NFL all has similar staining across all four mice. 
GFAP had staining in GCL and OPL. Collagen IV had staining at GCL, IPL, OPL, and 
RPE. NFL had staining at GCL, IPL, and OPL. Scale bar: 100 µm. Nuclei of cells are 
stained blue and proteins of interest are stained green (GFAP, Collagen IV, NFL, B-
Tubulin III) 
 
Growth factors (VEGF, TGF-β): 
Vascular epithelial growth factor (VEGF) is responsible for stimulating 
angiogenesis, epithelial cell growth, and vasculogenesis. VEGF plays a role in wet AMD 
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and diabetic retinopathy where there is new blood vessels formation in the retina causing 
loss in visual acuity. VEGF is expressed in the retina by Muller cells, endothelial cells, 
ganglion cells, RPE cells, and astrocytes. Immunoreactivity of VEGF is seen in the GCL 
and OPL. There seems to be an absence of VEGF staining in the knockout strain, and 
interestingly a decrease in the Cdh5-cre mice (Figure 5).  
Transforming growth factor beta (TGF-β) is a cytokine whose many functions 
include control of cell growth, cell proliferation, cell differentiation, and apoptosis. It is 
also linked with vascular barrier function, endothelial permeability, and angiogenesis 
which suggests it has a role in neovascularization (Walsh et al., 2009). It is expressed in 
ganglion cells, endothelial cells, and photoreceptors. Immunoreactivity of TGF-β is seen 
in the GCL and OPL in normal WT mice. There seems to be a decrease of staining in the 
knockout mice (Figure 5). 
 
Figure 5: IHC of Growth Factors in retina shows decrease expression in RORA 
knockout: VEGF and TGF-B is involved in angiogenesis and cell growth. 
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Immunoreactivity of both VEGF and TGF-B is low in Rora-floxed x Cdh5-Cre (D,F) 
compared to WT (A-C, E-G). Scale bar: 100 µm. Nuclei of cells are stained blue and 
proteins of interest are stained green (VEGF, TGF-B) 
 
Retinal Cell Specific Markers (Calbindin, Parvalbumin): 
Calbindin D-28K is a calcium binding protein. It is a retinal cell specific marker 
for horizontal cells in the retina.  Parvalbumin is a calcium binding protein. It is a retinal 
cell specific marker for amacrine cells in the INL.  IHC results show similar 
immunoreactivity in all mouse tissues for calbindin and parvalbumin.  
 
Photoreceptors (Blue opsin, Green opsin, Rhodopsin): 
Blue opsin, green opsin, and rhodopsin are markers for photoreceptor cells in the 
retina. Blue opsin are found in S-cone photoreceptor, green opsin are found in M-cone 
photoreceptor, and rhodopsin are found in rod photoreceptors. They are all expressed in 
the photoreceptor layer staining the different photoreceptors. All of the immunostaining 
were similar in the four different strains of mice (Figure 6). 
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Figure 6: IHC of Photoreceptors in retina shows no difference between RORA 
mutant and WT: S-cone, M-cone, and rod cells were stained by blue opsin, green opsin, 
and rhodopsin Ab respectively. All immunoreactivity of each protein were similar in both 
WT and mutant (A-L). Scale bar: 100 µm. Nuclei of cells are stained blue and proteins of 
interest are stained green (Blue opsin, Green opsin, Rhodopsin) 
 
Bipolar cells (Chx10, Synaptophysin, PKCα): 
Synaptophysin is a protein found in neurons involved in synaptic transmission. Its 
function is currently unknown but it is a part of the synaptic vesicle complex. It is found 
in both the inner plexiform layer (IPL) and outer plexiform layer (OPL) since this is 
where synaptic transmission occurs in the retina. Synapses of photoreceptors with bipolar 
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cells and horizontal cells occur in the OPL and Synapses of bipolar cells with ganglion 
cells and amacrine cells in the IPL. Immunoreactivity of synaptophysin is seen in the IPL 
and OPL as expected in WT, Rora-floxed, Cdh5-cre, and Rora-floxed x Cdh5-cre 
(Figure 7). 
Protein Kinase C alpha (PKCα) is a protein kinase that has many physiological 
roles and targets. It has been suggested that PKCα regulates bipolar cells signal 
transduction (Ruether et al., 2009). In the retina, it is mainly expressed in bipolar cells 
which are found in the inner nuclear layer (INL), OPL, and IPL.  
Chx10 is a protein that is involved in retina development. It is necessary in the 
developing retina where it helps retinal progenitor cells differentiate into mature cells. 
Chx10 expression is high in the developing retina, but in mature retina, it is confined to 
bipolar cells expressed at low levels.  Immunoreactivity of Chx10 is seen in the INL as 
expected in WT, Rora-floxed, Cdh5-cre, and Rora-floxed x Cdh5-cre (Figure 7). 
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Figure 7: IHC of Synaptophysin and Chx10 shows no change between RORA 
knockout and WT: Chx10 and Synpatophysin immunoreactivity were similar between 
WT and Rora-floxed x VE-Cdh-Cre tissues. Scale bar: 100 µm. Nuclei of cells are 
stained blue and proteins of interest are stained red (Synaptophysin, Chx10). 
 
CHROMATIN IMMUNOPRECIPTIATION – SEQUENCING (CHIP-SEQ) 
Chromatin immunoprecepitation with massively parallel sequencing is very useful 
in mapping DNA-protein interactions on a genomic-wide level. ChiP assay is an effective 
assay for transcription factors because binding of TF are very sequence specific, which 
leads to very localized ChiP-seq signals in the genome. ChIP data reveals numerous gene 
targets of RORA. 1150 genes were found to be statistical significant binding targets of 
RORA.  
 
INGENUITY:  INTEGRATED PATHWAY ANALYSIS 
AMD genes and RORA pathway genes were inputted into Ingunity IPA to 
analyze any known associations between these genes. Multiple pathways were found and 
linked to AMD (Figures 8-11). These genes were then compared to the list of RORA 
targets from the ChIP data. A list of genes appearing in both lists are our genes of 
interests which are RORA targeted genes that are linked with AMD (Table 2).  
  
 25 
AMD Genes Proteins that genes code for 
CFH Complement factor H 
ELOVL4 Elongation of very long chain fatty acids protein 4  
FBLN5 Fibulin-5 
FLT1 Vascular epithelial growth factor receptor 1 
MPDZ Multiple PDZ protein 
PLEKHA1 Pleckstrin homology domain-containing family A member 1 
TLR4 Toll-like receptor 4 
 
GPCR genes Proteins that genes code for 
DRD3 D3 dopamine receptor 
RAMP2 Receptor activity monitoring protein 2 
 
Transcriptional 
Regulator genes 
Proteins that genes code for 
CLDN3 Claudin 3 
CNPY2 Canopy FGF Signaling Regulator 2 
HIST1H2AD Histone H2A type 1-D 
MYCBP C-Myc binding protein 
RBM22 RNA binding motif protein 22 
RNF113A Ring finger protein 113A 
 
Cell signaling 
genes 
Proteins that genes code for 
ARHGAP19 Rho GTPase-activating protein 19 
EXOSC4 Exosome component 4 
PSD Pleckstrin and Sec7 Domain Containing 
RAB40C Ras-related protein Rab-40c 
 
Fatty Acid  
Metabolism genes 
Proteins that genes code for 
IGFBP1 Insulin-like growth factor binding protein 1 
N-cor Nuclear receptor co-repressor 1 
VLDLR Very low density lipoprotein receptor 
ZBTB9 Zinc finger and BTB domain containing 3 
 
Table 2: RORA targeted genes that may have associations with AMD: Genes from 
ChIP data was compared with Ingenuity pathway analysis to determine genes that are 
common. These genes are targets of RORA and genes that are also linked with AMD.  
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Figure 8: Association between AMD genes and fatty acid metabolic genes that are 
targets of RORA.: AMD genes are purple while fatty acid metabolism genes are orange. 
Lines and arrows show associations between the genes. Figure was produced by 
Ingenuity IPA. Genes of interest include: N-cor, PPARG, Smad, VLDLR, LDLR, 
IGFBP1, RARRES2, APOE3. 
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Figure 9: Association between AMD genes and GPCR genes that are targets of 
RORA. AMD genes are purple while GPCR genes are green. Lines and arrows show 
associations between the genes. Figure was produced by Ingenuity IPA. Genes of 
interests include: Beta arrestin, GPCR, RAMP2, DRD3 
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Figure 10: Association between AMD genes and cell signaling genes that are targets 
of RORA. AMD genes are purple while cell signaling genes are light blue. Lines and 
arrows show associations between the genes. Figure was produced by Ingenuity IPA. 
Genes of interst include ERK1/2, RAB40C, CLDN, PRKAC 
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Figure 11: Association between AMD genes and transcriptional regulator genes that 
are targets of RORA. AMD genes are purple while transcriptional regulator genes are 
red. Lines and arrows show associations between the genes. Figure was produced by 
Ingenuity IPA. Genes of interest include HIST1H2AD, PINKX1, 60S ribosomal subunit, 
E1F1B, PKA, MYCBP.  
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DISCUSSION 
 
A conditional knockout model was used to explore the effects of RORA in the 
retina. In the knockout model, RORA was conditionally knocked out in endothelial cells. 
The retinal pigment epithelium is a layer in the retina that supports, nourishes, and 
protects the retinal cells so that they can maintain normal visual function. Since the 
dysfunction of this layer of cells is critical in the development of AMD, we will study the 
effect of RORA knockout in these types of cells.     
Immunohistochemistry was performed to detect the levels of expression of 
various proteins and cell markers in the retina. Immunostaining of GFAP, NFL, Collagen 
IV, and β-Tubulin III were checked to see if RORA had any effect on structural proteins 
and structural changes in the retina. In addition, cell specific markers were also checked 
to see any changes in the different cells in the retina. Blue opsin, green opsin, rhodopsin, 
parvalbumin, and calbindin stains S-cone cells, M-cone cells, rod cells, amacrine cells, 
and horizontal cells respectively. IHC results shows that there is not much difference in 
levels of expression in either WT or RORA knockout (Figures 4, 6). In addition, we 
checked synaptophysin because it is important in normal neuron functions through its 
involvement in synaptic transmission. Synaptophysin expression was normal (Figure 7). 
Since RORA and Chx10 both are important in retinal cell differentiation and 
development, levels of Chx10 expression were also investigated which resulted in similar 
expression in WT and knockout (Figure 7).  
VEGF and TGF- β are growth factors whose functions include angiogenesis, 
vascular permeability, cell growth, cell differentiation, and vasculagenesis. IHC of VEGF 
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and TGF- β shows decrease levels of expression in RORA knockout compared to WT 
(Figure 5). This is an interesting finding due to the fact that neovascularization in the 
retina often leads to severe acute visual loss in wet AMD. CNV is a significant clinical 
manifestation of neovascular AMD, and recent studies have suggested the upregulation of 
angiogenic factors (VEGF, TGFB, angiostatin) to be involved in the formation of CNV 
(Zhang, 2007). In addition, a previous study suggested the presence of TGF-β in AMD 
pathophysiology (Silveira et al., 2010). Also, current treatment for wet AMD involves 
injections VEGF inhibitors to delay the progression of the disease (Kovach et al., 2012).  
Additional conformational experiments will be done to confirm that these changes are 
noted.  
Another important part of this study is to investigate the vast RORA pathway and 
how it is linked to AMD pathogenesis. Since RORA is a nuclear receptor that has been 
implicated in a variety of physiological functions (Solt et al., 2012), it will be invaluable 
to identify the gene targets of RORA. Using the ChIP-seq technique, we were able to 
determine the sequences of DNA that RORA binds to in vivo. Then, with software 
analysis, a list of statistically significant RORA gene targets was determined. Comparing 
this lists with a list of commonly known AMD genes, we determined a number of genes 
to further investigate (Table 2, Figures 8-11). Our results shows that AMD may have 
some associations with genes in a number of pathways including fatty acid metabolism, 
G-protein-coupled receptors, transcriptional regulation, and cell signaling.  
Fatty acid metabolism has been shown to be involved in AMD pathology and 
development. Cholesterol and lipids are major components of drusens, whose presence is 
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a clinical hallmark of AMD. In addition, recent studies have linked AMD risks to ATP 
binding cassette transporters, which are a major regulator of cholesterol and 
phospholipids (Allikmets, 2000). Our results have shown that IGFBP1, VLDLR, NCOR, 
and ZBTB9 are linked with AMD and are potential gene targets of RORA (Table 2, 
Figure 8). IGFBP1 is a binding protein that binds to IGF to extend its half-life to regulate 
its cellular availability (Juul, 2003). IGF has been shown to regulate metabolic processes 
and cell growth and development (Thissen et al., 1994), and recent studies have 
suggested that IGF1 and IGFBP1 have a role in AMD pathogenesis through the 
inflammatory pathway (Chiu et al., 2011). VLDLR is a transmembrane protein receptor 
that is involved in cholesterol uptake and fatty acid metabolism. Studies of VLDLR have 
shown in the absence of VLDLR, angiogenesis increases in the retina, a major 
complication in wet AMD (Hu et al., 2008; Jiang et al.2009).  
G-protein coupled receptors (GPCR) are the largest class of receptors and have 
roles in many physiological processes, including fatty metabolism, cell signaling, and 
transcriptional regulation. One example of a GPCR in the retina is rhodopsin, which is 
found in photoreceptors and is responsible for light transduction (Hamm, 2000). GPCR 
has been linked to the production of oxidation in the retina (Chen et al., 2012). Oxidative 
stress contributes to photoreceptor degeneration and damage to the retina, especially the 
RPE, which has implications in the development of AMD (Beatty et al., 2000). In 
addition, one current treatment for dry AMD is taking antioxidant multivitamins, which 
are shown to slow progression of the disease (AREDSRG, 2001).  
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Our data suggests that Rab40c and ARHGAP19 is targeted by RORA and is 
associated with the AMD pathway (Table 2, Figure 10). Rab40c and ARHGAP19 are 
small GTPase, which also links it to the GPCR pathway. Recent studies have shown that 
Rab40c is linked with formation and regulation of lipid droplets, which stores lipids and 
cholesterol (Tan et al., 2013). Lipid droplet dysfunction has a role in many metabolic 
diseases such as obesity and diabetes, which share risk factors for AMD (Greenberg et 
al., 2011). By linking AMD and RORA we can better understand the pathway in which 
AMD progresses and develops.  
Cell signaling is an important system that controls cellular activities and 
coordinates cellular actions. One example is that TGF-β downstream pathway includes 
many extracellular signal-regulated kinases (ERK/MAP) targets in order to induce its 
effects on the cells (IKushima and Miyazono, 2010). In addition, an important signaling 
pathway of AMD involves the immune system. Immune-mediated responses and 
inflammatory processes has a role in drusen formation and promoting CNV in the retina 
(Hageman et al., 2001). Chemokines (IL-6, CCL2, CCR2, CX3CR1, TNF), cell signaling 
molecules in immune processes, have been linked to AMD since they have shown 
damaging effects on Bruch membrane, RPE, and the retina (Ambati, Atkinson, and 
Gelfand, 2013). Also, AMD risk has been strongly linked with the complement cascade 
system; drusens contain almost all the complement proteins. Genetic variations in 
complement genes (CFH, C3) have shown an increase risk for the disease (Klein et al., 
2005).   
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Transcriptional regulation affects gene and protein expression. RORA is a 
transcriptional factor that regulates many different gene targets (Jetten et al., 2009), and it 
would be expected that RORA also have some targets that has a function in transcription. 
This will be important in elucidating a pathway on how RORA has an effect in AMD 
pathogenesis.  
The next step of this study is to further explore the targeted RORA genes that 
have been linked to AMD. Quantitative real-time PCR will be performed to investigate 
how these gene expression levels are affected in the conditional RORA knockout mice. 
Genes that show altered expression levels will be promising targets to further analyze. In 
addition, we will further investigate the role of RORA in the retina and in the etiology of 
AMD. Future studies will explore the effect of RORA in the retina of conditional 
knockout of RORA in cone cells and Chx10. By exploring these knockout models, we 
will gain a better understanding of the role of RORA in the photoreceptors and the 
developing retina.   
 AMD is the one of the most prevalent causes of decrease in visual acuity and 
irreversible blindness in the world. AMD is a complex genetic disease that has a number 
of genes and environmental factors that is implicated in its etiology. There is currently no 
cure for AMD, but because of its negative effect on quality of life, high economic costs, 
and public health implications, there is an increasing urgency for research in this area 
(Day et al., 2011; Soubrane et al., 2007). RORA has been linked with AMD 
pathogenesis, and it is a promising area to explore to because of its effects in the retina 
and numerous physiological pathways. This study is one small step towards elucidating 
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both the etiology of AMD and the role of RORA in AMD. This will be very beneficial to 
developing novel treatments and therapeutic drugs targets to cure this disease in the 
future. 
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